IngredientsFucose is a hexose deoxy sugar with the chemical formula C6H12O5. More precisely, it is a six-carbon sugar also known as 6-deoxy-L-galactose, with a molecular formula of C6H12O5 and a melting point of 150.0–153.0 °C. It is a white crystalline powder that easily absorbs moisture, and its hydrophilicity is weaker than that of other monosaccharides.
L-fucose is the main form of fucose found in nature and is also the only levorotatory sugar used by mammals, while D-fucose is found only in some glycosides. Most naturally occurring sugars, such as galactose, are present in the D-configuration; notably, the C-6 carbon of L-fucose lacks a hydroxyl group present at the C-6 position of D-galactose. This structural absence of a hydroxyl group classifies fucose as a deoxy sugar, and it is also described chemically as 6-deoxy-L-galactose.
The word "fucose" comes from the Latin fucus, meaning "seaweed," and the conventional suffix -ose for carbohydrates and sugars.
L-fucose is a naturally occurring sugar widely found in nature, appearing in many bacterial and plant glycosides and polysaccharides. In mammals, it is found as a component of glycoproteins and glycolipids on cell surfaces. It is found on N-linked glycans on the mammalian, insect, and plant cell surface.
Fucose is the fundamental sub-unit of the seaweed polysaccharide fucoidan. Commercially available fucoidan is commonly extracted from the seaweed species Fucus vesiculosus (wracks), Cladosiphon okamuranus, Laminaria japonica (kombu, sugar kelp), and Undaria pinnatifida (wakame). The main source of fucoidan (and thus of L-fucose as a polysaccharide constituent) is the extracellular matrix of brown seaweed (Phaeophyta), but it can also be isolated from invertebrates such as sea urchins (Echinoidea) and sea cucumbers (Holothuroidea).
Fucose-containing carbohydrates (FCCs) derived from marine organisms such as seaweed, invertebrates, microalgae, fungi, and bacteria have garnered growing attention due to their diverse bioactivities and potential therapeutic applications. In human biology, L-fucose is abundantly present in human milk oligosaccharides (HMOs). In human milk oligosaccharides, L-fucose is the abundant component, a major distinguishing feature between human and bovine milk. Endogenous free L-fucose is derived from intracellular recycling via hydrolysis and liberation during the recycling of proteoglycans in lysosomes; in contrast, exogenous (dietary) L-fucose is found in a variety of plants.
Fucose has been obtained from natural sources, synthesized chemically or enzymatically from monosaccharides, and produced by microbe-assisted processes. Regarding fucose production from natural sources, fucose-containing oligosaccharides that can be isolated from biomass, preferably from algae by extraction, are hydrolyzed to provide a complex mixture containing fucose as well as related sugars and/or derivatives thereof. Recovery of the fucose has typically required sophisticated separation techniques such as chromatography with anion or cation exchange resins, dialysis, and fractional crystallization.
As a supplement or food ingredient, L-fucose appears in several forms:
Marine seaweeds constitute an important part of the diet in many parts of Asia, and seaweeds have also been used in traditional medicine since prehistoric times. Because fucose is inseparable from its primary dietary source — brown seaweeds and their polysaccharide fucoidan — the historical use of fucose is best understood through the traditional use of seaweed-derived foods and medicines.
Historically, seaweeds have had traditional usage, especially in Asian countries, as herbal medicine for the treatment of tumors, neurodegenerative diseases, urinary problems, and gastrointestinal issues. Brown seaweeds containing fucoidan are extensively used as part of the regular diet in East Asia, particularly in Japan, China, and Korea. Despite their use in traditional Chinese and Japanese folk medicines, only in the current years have they been commercialized as nutritional supplements and pharmaceutical products.
Many species of marine algae have long been used in food diet and also documented as being used in traditional oriental medicine for over 1,000 years. Fucoidan has been used as an anticancer drug in traditional Chinese medicine. Some Western herbal products containing F. vesiculosus are known to be used topically for the treatment of sore knees, healing wounds, and also as herbal teas for their laxative or weight-control effects. F. vesiculosus has also been reported for treatment of the uterus and ovaries in the Caribbean islands.
It is important to note that traditional practices employed whole seaweeds or crude seaweed preparations containing the fucoidan polysaccharide (which is rich in L-fucose), rather than purified L-fucose monosaccharide itself. Isolated, purified L-fucose as a deliberate dietary supplement is a modern development; L-fucose has been studied as a chemical entity since the 1960s.
Fucose is a 6-deoxy hexose in the L-configuration found in a large variety of different organisms. In mammals, fucose is incorporated into N-glycans, O-glycans, and glycolipids by 13 fucosyltransferases, all of which utilize the nucleotide-charged form, GDP-fucose, to modify targets.
Fucose can be incorporated into the terminal portions of N-, O-, or lipid-linked oligosaccharide chains, modify the core of complex N-glycans, or can be linked directly to serine or threonine residues in some proteins. The conjugation of glycoproteins and glycolipids with the dietary sugar L-fucose is known as fucosylation.
In humans, fucose is incorporated into glycans using GDP-fucose as a nucleotide sugar donor. It can be synthesized directly from exogenous fucose or from fucose salvaged from glycoprotein degradation; both require subsequent actions of fucokinase (FCSK) and fucose-1-phosphate guanylytransferase (FPGT) to "activate" fucose. Alternatively, GDP-fucose can be produced de novo from either mannose or glucose; in this process, GDP-mannose is converted to GDP-fucose in a three-step reaction catalyzed by two enzymes — GDP-mannose 4,6-dehydratase (GMDS) and GDP-fucose synthetase (GFUS).
One of the characteristic roles of fucose is its regulation of selectin-dependent leukocyte adhesion, which has been well studied over the last two decades. In mammals, fucose-containing glycans have important roles in blood transfusion reactions, selectin-mediated leukocyte-endothelial adhesion, host-microbe interactions, and numerous ontogenic events, including signaling events by the Notch receptor.
Inactivation of FUT7 causes a severe deficit in selectin-dependent endothelial cell adhesion and lymphocyte homing. Fucose modifications on glycolipid E-selectin receptors are required for neutrophil extravasation during inflammation.
Three of the fucosyltransferases — FUT8, FUT12/POFUT1, and FUT13/POFUT2 — are essential for proper development in mice. Fucose modifications on Notch receptor EGF-like repeats are required for receptor-ligand recognition during embryonic development, cell fate specification, and organogenesis.
The A, B, and H blood group antigens are α1,2-linked fucose-containing glycans present on glycoproteins and glycolipids of erythrocytes. The enzyme fucosyltransferase 1 (FUT1) is responsible for the synthesis of ABH antigens on erythrocytes; the ABH antigens are also expressed in mucus and other secretions, where their expression is generated by fucosyltransferase 2 (FUT2). In ABH secretor individuals (approximately 80% of Caucasians), fucosyltransferase 2 converts type 1 N-acetyllactosamine glycan chains to H antigen, which functions as a precursor for the A, B, and Lewis b antigens. Non-secretor individuals do not express active fucosyltransferase 2 enzyme due to a nonsense mutation in the FUT2 gene and therefore cannot express the ABH antigens in their mucus and other secretions.
FUT2 secretor status has broader implications for disease susceptibility: many studies have demonstrated that the interaction of histoblood group antigens (HBGAs) with the host microbiota is a cause of pathogenesis of intestinal diseases, making FUT2 non-secretor a risk factor for inflammatory bowel disease (IBD); as HBGAs also act as attachment sites for norovirus and rotavirus, the non-secretor status becomes a protective factor for both viral infections.
Fucoidan is a sulphated polysaccharide extracted from brown marine algae and consists of L-fucose and sulfate ester groups. Interest in fucoidan is related to its broad biological activity, including possible antioxidant, anti-inflammatory, antifungal, antiviral, and antithrombotic effects. The negative charge of the molecule results from the presence of sulfate residues in the C-2 and C-4 positions, occasionally in C-3, allowing the formation of complexes with other oppositely charged molecules.
This represents the most clinically established use of oral L-fucose supplementation, with case-level human evidence.
LAD2 is a rare congenital disorder of glycosylation caused by mutation of the gene encoding a GDP-fucose transporter in the Golgi apparatus (SLC35C1). LAD2 is characterized by immunodeficiency, leukocytosis without pus formation, mental retardation, and growth retardation, all directly attributed to the absence of neutrophil sialyl Lewis X, of which fucose is an essential component.
A landmark 1999 publication in The New England Journal of Medicine documented the first therapeutic use of oral fucose in LAD II. The investigators described a simple, noninvasive, and effective therapy for LAD II, a rare inherited disorder of fucose metabolism, which leads to an immunodeficiency caused by the absence of carbohydrate-based selectin ligands on neutrophils as well as severe psychomotor and mental retardation. The fucosylation defect in LAD II fibroblasts was correctable by addition of L-fucose to the culture medium, which prompted initiation of dietary fucose therapy. Oral supplementation of fucose induced the expression of fucosylated selectin ligands on neutrophils and core fucosylation of serum glycoproteins. During 9 months of treatment, infections and fever disappeared, elevated neutrophil counts returned to normal, and psychomotor capabilities improved.
Subsequent case reports extended these findings. In one patient, therapy with oral fucose led to the disappearance of chronic skin infections and improvements in behavior and attention span; L-fucose therapy led to considerable clinical improvement of chronically inflamed skin and mental status.
A 2022 study in the American Journal of Medical Genetics Part A examined milder variants of the disorder. Some patients with LAD II benefit from oral fucose therapy, though this had not been previously studied in patients with milder disease. The study described two new patients from separate families with the milder variant of LAD II, demonstrating improvement in speech and cognition, CD15 expression, and core fucosylation of serum glycoproteins after 27 months of oral fucose supplementation in one patient.
More recently, a 2026 report described a patient with global hypofucosylation associated with a monoallelic SLC35C1 variant in whom L-fucose supplementation led to subsequent improvements in weight and head circumference, normalization of IgG levels, and remarkable developmental catch-up.
Cell-based research has clarified why supplementation works in some — but not all — patients: although mutated SLC35C1 caused different α-1–6 core fucosylation of N-glycans explaining more or less severe disorder symptoms, the differences practically disappeared after external fucose supplementation, with fucosylation restored to the level observed in healthy cells, indicating that additional fucose in the diet should improve the condition of all patients. An ongoing clinical trial (ClinicalTrials.gov ID: NCT05462587) is enrolling patients aged 6 months to 75 years with biochemically and genetically proven LAD II to formally evaluate the efficacy and safety of a pharmaceutical-grade fucose formulation (AVTX-803).
Evidence strength: Compelling case-level and small case-series human evidence with mechanistic support. No randomized controlled trials (RCTs) have yet been published for this indication.
The fucose-containing HMO 2′-fucosyllactose (2′-FL) has been the focus of clinical research on gut microbiota composition and gastrointestinal health.
2′-FL, one of the most abundant oligosaccharides in breast milk, functions as a selective prebiotic. Breast milk is rich in bioactive components, especially HMOs, which are crucial for establishing gut microbiota.
In infants, a 2025 randomized clinical trial enrolled three groups to evaluate the effect of adding 2′-FL to infant formula: an HMO experimental group (n = 29), a GOS/FOS control group (n = 30), and an exclusively breastfed reference group (n = 28), with fecal samples analyzed in the first and fourth months of life.
In adults with chronic gastrointestinal conditions, a pilot study examined both in vitro and clinical effects of 2′-FL. 2′-FL, a prebiotic human milk oligosaccharide, is considered bifidogenic and butyrogenic. To assess prebiotic effects, in vitro experiments were conducted on stool from healthy, IBS, and ulcerative colitis adult donors; in anaerobic batch culture fermenters, Bifidobacterium and Eubacterium rectale–Clostridium coccoides counts and short-chain fatty acids including butyrate increased during fermentation with 2′-FL and some 2′-FL/probiotic combinations. In a subsequent open-label pilot trial, the effect of a 2′-FL-containing nutritional formula was evaluated in twelve adults with IBS or ulcerative colitis.
A 6-week RCT in older adults (RAMP Study, NCT03690999) provided more rigorous evidence. This 6-week randomized controlled trial evaluated whether 2′-FL could improve gut microbiota and immune function in 89 healthy older adults (mean age 67.3 years). While the primary endpoint of cytokine response change was not met, 2′-FL supplementation increased gut Bifidobacterium levels and elevated serum insulin, HDL cholesterol, and FGF21 hormone. Bifidobacterium "responders" experienced additional metabolic and proteomic changes and also performed better on a cognitive test of visual memory. Nonresponders were more likely to lack Bifidobacterium in their gut microbiota at the start of the intervention.
More broadly, fucose, fucose-containing oligosaccharides, and fucose-containing polysaccharides have been widely applied in the fields of food and medicine, including applications in Helicobacter pylori eradication and renal function protection.
Evidence strength: Moderate for bifidogenic effects of 2′-FL in infants and adults; the RAMP RCT did not meet its primary immunological endpoint. Evidence for broader gastrointestinal therapeutic effects in IBD and IBS remains preliminary (pilot studies, small n).
Fucosylation plays a dual and context-dependent role in cancer biology. The conjugation of glycoproteins and glycolipids with the dietary sugar L-fucose is known as fucosylation; recent work has shown how fucosylation is deregulated in cancer, influencing tumour progression and therapeutic responses, and how it might be leveraged to treat cancer.
A major 2023 study published in Nature Cancer by Lau et al. at Moffitt Cancer Center demonstrated that dietary administration of L-fucose induces fucosylation and cell surface enrichment of the MHC-II protein HLA-DRB1 in melanoma cells, triggering CD4+ T cell-mediated increases in intratumoral immune cells and anti-tumor immunity, enhancing immune checkpoint blockade responses. Melanoma fucosylation and fucosylated HLA-DRB1 associate with intratumoral T cell abundance and anti-PD1 responder status in patient melanoma specimens, suggesting the potential use of melanoma fucosylation as a strategy for stratifying patients for immunotherapies.
In preclinical mouse models, in NRAS- and BRAF-mutant melanoma models, dietary L-fucose suppressed tumor growth by approximately 50–60% and increased tumor-infiltrating lymphocytes (TILs) by approximately 10–50-fold; of all TIL subpopulations examined, CD3+ T cells were most increased by L-fucose, doubling or increasing by 15-fold.
In contrast to efforts aimed at inhibiting fucosylation for the treatment of cancers, increasing fucosylation has also been reported to elicit therapeutically potent antitumor effects with the potential to augment immunotherapies. The fucosylation-triggered tumor suppression appeared immune-mediated, as overall immune infiltration of melanomas was increased by L-fucose supplementation; the ex vivo treatment of CD8+ T cells with exogenous recombinant FUT7 before adoptive cell transfer into melanoma-bearing mice resulted in increased T-cell fucosylation associated with enhanced cytotoxic activities in vitro and melanoma tumor suppression in vivo.
It was reported that L-fucose was an effective agent for harmlessly enhancing intratumoral immune cells and immunotherapy efficacy in melanoma.
Regarding fucoidan (the fucose-rich polysaccharide) more broadly, fucoidan has various biological and pharmacological activities, such as anti-cancer/anti-tumor, anti-proliferation, anti-inflammatory, and immune-modulatory functions, and fucoidan-related dietary supplements and nutraceuticals have recently drawn considerable attention. However, as of 2019, only laboratory studies, early-stage clinical trials, and case reports have been reported on the potential biological properties of fucoidan, and this characterization has not been substantially updated with pivotal RCT data.
Evidence strength: Highly promising preclinical (animal model) and correlational human data for L-fucose in melanoma immunotherapy. The mechanistic work published in Nature Cancer (2023) is significant but represents preclinical and translational research; no interventional clinical trials in cancer patients using oral L-fucose supplementation have been completed and published as of 2025–2026.
A growing body of preclinical research points to fucose as a neuromodulatory compound. Fucosylation, a major glycan modification, has been shown to influence neuronal and microglial mechanisms, but whether unconjugated free L-fucose can affect brain function was, until recently, unknown. L-fucose can be transported into cells and metabolized by fucokinase (FCSK) via the poorly understood salvage pathway.
Research published in Science Advances (2025) demonstrated novel neuromodulatory properties. Using mouse hippocampal slices, investigators showed that L-fucose enhanced excitatory neurotransmission and long-term potentiation (LTP) through regulation of presynaptic release; these effects required L-fucose to be metabolized through the FCSK-driven salvage pathway, suggesting a metabolic-signaling mechanism. Human Alzheimer's disease (AD) and 5xFAD mouse brains showed signs of fucose hypometabolism with impaired L-fucose signaling; such abnormalities were corrected by exogenous L-fucose, exemplified by rectification of LTP deficits in 5xFAD hippocampus. A dietary L-fucose supplement, which increased cerebral free L-fucose levels and up-regulated FCSK to drive the salvage pathway, mitigated synaptic and behavioral deficits of 5xFAD mice; the data suggest an unrecognized neuromodulatory function of free L-fucose and reveal its therapeutic potential.
In a 2024 study of neuroinflammation: exogenous L-fucose attenuated LPS-induced IL-6 mRNA expression in cerebral tissues; the activation of microglial cells, which provoke neuroinflammatory responses upon LPS stimulation, was inhibited by L-fucose preadministration; and L-fucose suppressed downstream intracellular signaling of IL-6, including the phosphorylation levels of JAK2, Akt, and STAT3. These results indicated that L-fucose administration ameliorates LPS-induced neuroinflammation, suggesting that core fucosylation plays a vital role in anti-inflammation and that L-fucose is a potential prophylactic compound against neuroinflammation.
Evidence strength: Entirely preclinical (mouse models, in vitro). No human clinical trials have been conducted or published investigating L-fucose for neurological indications. The Science Advances (2025) work is mechanistically compelling but requires human translation.
High-salt diet consumption reduced the abundance of the gut microbial metabolite L-fucose, leading to a more substantial inflammatory response in mice. A high-salt diet led to increased peritonitis incidence in mice, as evidenced by increased accumulation of inflammatory cells and elevated levels of inflammatory cytokines, including TNF-α, IL-6, and MCP-1. These findings suggest that L-fucose could be a potential therapeutic agent for reducing inflammation in the context of a high-salt diet; however, further research is needed to elucidate the precise mechanisms and to explore its potential for clinical application.
Fucose moieties on cell-surface glycans are increasingly recognized as critical to many cell-cell interaction and signaling processes. One of the characteristic roles of fucose is its regulation of selectin-dependent leukocyte adhesion. Recent studies of fucose in immune cell development and function regulation have significantly expanded the contemporary understanding of fucosylation.
Evidence strength: Preclinical (animal models and cell studies). Human evidence is limited to indirect inferences from genetic studies and the clinical LAD II literature.
Fucose-containing carbohydrates (FCCs) have been identified as potential anticancer agents against gastric and colon cancers, involving mechanisms of targeting cancer cells, regulating apoptosis and autophagy, and inhibiting tumor metastasis. These mechanisms have primarily been characterized in cell lines and animal models, with limited human evidence.
The following dosages are reported directly as stated in cited sources; they are not recommendations.
Oral supplementation of fucose in an LAD II patient induced the expression of fucosylated selectin ligands on neutrophils and core fucosylation of serum glycoproteins; during 9 months of treatment, infections and fever disappeared, elevated neutrophil counts returned to normal, and psychomotor capabilities improved. The published case series and reports generally describe oral dosing in milligrams per kilogram of body weight, titrated individually, though precise published weight-based doses for individual patients vary across case reports.
In mouse studies, the Fut8::hIL6-Luc mice were treated with L-fucose at 12 or 36 mg/day for 2 weeks and then intraperitoneally injected with LPS on the 15th day to assess neuroinflammatory outcomes.
Randomized studies supplementing 2′-FL (alone or with other HMOs) in healthy adults reported good tolerability across 5–20 g/day for two weeks, with microbiota shifts toward Bifidobacterium.
Human clinical studies showed no toxicity of fucoidan from U. pinnatifida at a level of 3 g/day for 12 days. Animal repeat-dose studies showed no significant toxicological changes in a 6-month study of fucoidan from Laminaria japonica at 300 mg/kg bw/day, and no significant toxicological changes in 3-month study at 600 mg/kg bw/day or in 28-day studies at up to 1,350 mg/kg bw/day (rodent data).
Results of a 13-week dietary toxicity study provided with an in utero phase, together with negative genotoxicity results, support the safety of L-fucose dietary consumption in humans at a suggested acceptable daily intake (ADI) of 5 mg/kg body weight. The anticipated average ranges of dietary daily intake to L-fucose based on data from the EFSA Comprehensive Food Consumption Database are below this ADI.
L-fucose is a hexose-deoxy-sugar endogenous in mammals and is one of the eight essential monosaccharides to humans. This rare sugar is involved in a wide array of biological functions. L-fucose is also a building block in several naturally occurring oligo- or polysaccharides. This monosaccharide has been consumed to a significant degree by humans for centuries.
L-fucose is not genotoxic or mutagenic based on available regulatory safety data submitted to the European Food Safety Authority. L-fucose has been demonstrated as a generally safe and well-tolerated therapeutic agent in patients with leukocyte adhesion deficiency II.
For fucoidan (the polymeric fucose-rich compound): fucoidan is a non-toxic, biodegradable, and biocompatible compound approved by the FDA as Generally Recognized As Safe (GRAS) as a food ingredient. However, as of 2019, only laboratory studies, early-stage clinical trials, and case reports had been reported on the potential biological properties of fucoidan, and there is little evidence for safe use of fucoidan products, as no national regulatory authorities have designated it as safe for human use and no rigorous clinical safety trials have been reported.
Animal safety data indicate a wide margin; however, translation to human safety at high supplemental doses remains to be formally established through rigorous clinical trials. There is high variation in the quality of products containing fucoidan. Iodine co-extraction from seaweeds is a practical consideration with crude extracts, though purification steps remove this contaminant.
Fucoidan shows a wide range of biological activities including anticoagulant, anti-inflammatory, antidiabetic, procoagulant, anticancer, and antiviral activities. The structural similarity of sulfated fucose polymers to heparin (a known anticoagulant) raises a theoretical concern about additive effects with anticoagulant or antiplatelet medications. This interaction has not been formally characterized in human clinical trials but is a biological plausibility concern noted in the pharmacological literature.
An important nuance in the cancer biology literature is that fucosylation can be both tumor-promoting and tumor-suppressing depending on context. In addition to supplementation with L-fucose in preclinical cancer models, a seaweed-derived L-fucose-rich extract called fucoidan has exhibited antitumorigenic properties in vivo and in vitro. Fucosylation appears to be a posttranslational modification that can be therapeutically targeted, as manipulating the molecular underpinnings of fucosylation has been shown to be sufficient to impair or block tumor progression and to modulate antitumor immunity. However, in other cancer contexts, enhanced fucosylation of antibodies reduces NK cell cytotoxicity. This bidirectionality means that supplemental L-fucose cannot be universally characterized as antitumorigenic in all cancer types, and no human intervention trials exist to guide this discussion.
Individual response to fucosylated prebiotic compounds may be modified by FUT2 secretor genotype, which determines the baseline expression of fucosylated glycans in intestinal mucus. Nonresponders to 2′-FL supplementation were more likely to lack Bifidobacterium in their gut microbiota at the start of the intervention, suggesting that baseline microbiome composition—potentially influenced by secretor status—can predict responsiveness.
Although fucoidan has been used in traditional Chinese medicine, it has not been approved as a human drug in any country, and no advanced clinical trials have been reported as of 2019. Free L-fucose is being evaluated as a novel food ingredient by the European Food Safety Authority (EFSA), and a pharmaceutical-grade formulation (AVTX-803) is in clinical trials for LAD II. Currently, fucoidan is not approved for medical applications.
Health conditions that Fucose may help support.
Body systems that Fucose may help support.
Go back